prior to conducting this study. A total of 520 patients underwent surgery for an intracranial primary (de novo) GBM at a single academic tertiary-care institution (The Johns Hopkins Hospital) between 1997 and 2007. The pathology was determined by a senior neuropathologist in all cases, and the grading criteria were based on the WHO classification system. 15, 21 Patients at least 18 years old with a tissue-proven diagnosis of a primary supratentorial GBM (WHO Grade IV) were included in the study. Patients who had undergone prior resections, previous adjuvant therapy (chemotherapy or radiation therapy), infratentorial gliomas, and/or needle biopsies were excluded from the analysis. Patients with incomplete medical records lacking data with respect to clinical presentation, pre-and postoperative MR imaging, and/or adjuvant therapies were also excluded. This was done to create a more uniform patient population with similar tumor types, tumor location, and treatment strategies.
Recorded Variables
The clinical, operative, and hospital course records of the patients who met the inclusion criteria were retrospectively reviewed. The information collected from neurosurgery and neurooncology clinical notes included patient demographic characteristics, comorbidities, presenting symptoms, results of neuroimaging, neurological function, and adjuvant therapy. The KPS index was used to classify patients' preoperative functional status; 9 KPS indices were based on notes obtained during the last preoperative clinical visit and were assigned during chart review by a reviewer blinded to outcome. A motor deficit was defined as decreased strength, while sensory loss was decreased sensation to light touch as identified by a clinician during a physical examination. A language deficit was defined as any combination of receptive and/ or expressive aphasia.
The MR images were obtained and reviewed. The characteristics that were recorded included the lesion's size (largest diameter based on FLAIR images), specific lobe involvement, and adjacency to the lateral ventricles. The tumor was defined as periventricular if it bordered the lateral ventricles on contrast-enhanced MR imaging, as previously defined. 4 Additionally, the tumor was categorized as involving eloquent cortex if it involved the motor/sensory cortex, language cortex, or the basal ganglia/internal capsule. These characteristics were assigned by a clinician blinded to patient outcomes. Extent of resection was classified from dictations of MRIs obtained < 48 hours after resection as either GTR or STR by an independent neuroradiologist blinded to patient outcomes; STR and GTR were defined as having residual and no residual enhancement, respectively.
The date of death was assessed by accessing the social security index database. 29 This database was last queried on May 1, 2009. Perioperative death was defined as death within 30 days of surgery. In cases in which death could not be confirmed in the database, the patients were classified as lost to follow-up at the time of their last clinic visit.
Perioperative Treatment
The general aim of surgery was to achieve GTR of the tumor when possible. Cases in which STR was performed were mainly those in which the tumor involved eloquent brain as confirmed by intraoperative mapping and/or monitoring (awake/speech language mapping, direct cortical motor stimulation, and motor evoked or somatosensory evoked potentials). Motor and somatosensory evoked potentials were routinely used in the majority of cases, while surgical navigation (CT and/or MR imaging wand) was used in all cases after 2001. The use of motor mapping or electrocorticography largely depended upon the preference of the surgeon. Motor or speech mapping were primarily used when the tumor was near the speech or motor cortex, respectively.
The use of polifeprosan with carmustine (BCNU) implant therapy was determined by the surgeon and patient. These carmustine wafers were typically not implanted when tumors were multifocal, extended across the corpus callosum, or required large opening of the ventricle. Likewise, the particular use of adjuvant radiation and chemotherapy was determined by the surgeon, radiation oncologist, medical oncologist, and the patients themselves.
Statistical Analysis
Summary data were presented as means ± SDs for parametric data and as medians with IQRs for nonparametric data. A priori power analysis (JMP 7, SAS Institute) was conducted to evaluate whether the study was significantly powered. A cutoff of value 0.80 was preassigned as being of sufficient power. For intergroup comparison, the Student t-test was used for continuous data and the Mann-Whitney U-test for categorical data. Values with p < 0.05 were considered statistically significant.
Survival as a function of time was plotted using the Kaplan-Meier method, and the Log-rank analysis was used to compare Kaplan-Meier plots (GraphPad Prism 5). Multivariate proportional hazards regression analysis was used to identify preoperative factors associated with survival for patients with GBM. This was done after controlling for intra-and postoperative factors (extent of resection, 17, 19, 22 carmustine wafer implanation, 2,34 temozolomide chemotherapy, 12, 31 and radiation therapy 10 ) known to be associated with survival. In this analysis, all variables associated with survival in univariate analysis (p < 0.10) were included in a step-wise multivariate proportional hazards regression model. Values with p < 0.05 in these analyses were considered statistically significant.
Results

Preoperative Characteristics
The preoperative characteristics of the patients in this study are summarized in Table 1 . A total of 520 patients underwent resection of a primary GBM during the reviewed period. Of these 520 patients, 393 met the inclusion criteria. The mean age of these 393 patients at the time of surgery was 58.6 ± 13.6 years, and 237 (60%) were male. The median preoperative KPS score was 80 (IQR 80-90), and the major presenting symptoms were headaches in 119 (30%), motor deficits in 111 (28%), language deficits in 100 (25%), and seizures in 79 (20%). The mean tumor size was 4.3 ± 1.5 cm, and 174 (44%) of the tumors involved the frontal lobe, 72 (18%) the parietal lobe, 119 (30%) the temporal lobe, and 24 (6%) the occipital lobe. The tumor primarily involved the cortex in 146 (37%) and was periventricular in 104 (26%), 112 (28%) involved eloquent cortex, with 38 (10%) involving the motor/sensory cortex, 32 (8%) the language cortex, and 42 (11%) the basal ganglia/internal capsule.
Perioperative and Postoperative Outcomes
The peri-and postoperative outcomes are summarized in Table 1 . Gross-total resection was achieved in 191 (49%) of patients. There were 4 cases of perioperative death (a rate of 1%). In 148 cases (38%), carmustine wafers were placed at the time of surgery, while 192 patients (49%) underwent temozolomide chemotherapy. Of the 192 patients who received temozolomide therapy, 107 (56%) received temozolomide according to the protocol used in Stupp et al. 31 In 260 cases (66%), the patients received radiotherapy, with a median dose of 6000 cGy (IQR 5940-6000 cGy).
At last follow-up, 310 patients (79%) had died. The median follow-up time for all patients was 10.4 months (IQR 4.7-16.5 months), while the median follow-up time for surviving patients was 10.5 months (IQR 6.5-20.7 months). The median survival of the entire cohort was 11.9 months, with the 6-, 12-, 18-, and 24-month survival rates being 74.3, 45.1, 28.9, and 19.5% respectively.
Factors Independently Associated With Duration of Survival
Univariate Analysis. In univariate analysis, the factors significantly associated with shortened survival were: older age, diabetes, depression, decreased preoperative KPS score, motor deficits, language deficits, cognitive deficits, cortical involvement, and periventricular tumor location. No other clinical or imaging variables were found to be significantly associated with survival. The variables for which no significant association was found included sensory deficits, visual deficits, tumor size, and involvement of eloquent, motor/sensory, or language cortex (Table 2) .
Multivariate Analysis. In multivariate analysis, after controlling for extent of resection, carmustine wafer (Table 2) . Of note, the variables age and KPS score were subdivided to find which age and KPS score had the strongest statistical association in the multivariate model. Age was categorized into decades. Statistically significant associations with shortened survival were found for ages greater than 40 years (p = 0.04), 50 years (p = 0.02), 60 years (p < 0.001), and 70 years (p = 0.001). However, among these age categories, age older than 60 years (HR 1.731, 95% CI 1.370-2.186, p < 0.001) had the greatest statistical association with shortened survival. In addition, KPS score categories were analyzed; KPS scores ≤ 80 (p < 0.001), ≤ 70 (p = 0.02) and ≤ 60 (p = 0.02), but not ≤ 90 (p = 0.16), were significantly associated with shortened survival. However, among these KPS score categories, KPS score ≤ 80 at the time of surgery (HR 1.603, 95% CI 1.263-2.037, p < 0.001) had the greatest statistical association with shortened survival.
Prognostic Classes and Differential Survival
Based on the multivariate analysis, a prognostic classification scale was devised (Table 3) . One point was assigned for each factor independently associated with decreased survival. One point each was assigned for patients older than 60, KPS score ≤ 80, motor deficit, preoperative language deficit, and periventricular tumor location at the time of surgery. Patients therefore could have a prognostic score ranging from 0 to 5. Patients receiving a score of 0-1, 2, 3, and 4-5 were assigned prognostic classes of 1, 2, 3, and 4, respectively (Table 4) .
Prognostic classes 1, 2, 3, and 4 included 143, 122, 83, and 45 patients, respectively (Table 4 ). An a priori power analysis was conducted and showed that there was sufficient power (> 0.90) to detect significant differences in treatment regimens between these 4 classes. Gross-total resection was achieved in 77 patients (54%) in Class 1, 53 (43%) in Class 2, 38 (46%) in Class 3, and 23 (51%) in Class 4. There were no significant between-class differences with respect to the percentage of patients in whom GTR was achieved. Carmustine wafers were placed in 60 (42%) of the patients in Class 1, 44 (36%) in Class 2, 28 (34%) in Class 3, and 16 (36%) in Class 4. There were no significant between-class differences in the percentage of patients who had carmustine wafer implantation. Temozolomide was administered to 77 (54%) of the patients in Class 1, 59 (48%) in Class 2, 37 (45%) in Class 3, and 19 (42%) in Class 4. There were no significant between-class differences in the percentage of patients who received temozolomide. Lastly, regarding radiation, 98 patients (69%) received radiation in Class 1, 83 (68%) in Class 2, 48 (58%) in Class 3, and 31 (69%) in Class 4. As with the other treatment regimens, there were no significant between-class differences in the percentage of patients who received radiation therapy. In addition, a total of 115 patients (29%) received carmustine wafer implantation, temozolomide chemotherapy, and radiation therapy; 42 (29%) patients in Class 1, 34 (28%) in Class 2, 24 (29%) in Class 3, and 15 (33%) in Class 4 received this triple regimen. There were no significant differences between these classes in the percentage of patients receiving this triple regimen.
Patients with a prognostic class of 1 had a median survival of 16.6 months, with 6-, 12-, and 18-month survival rates of 89.1, 65.2, and 46.4%. Patients with a prognostic class of 2 had a median survival of 10.2 months, with 6-, 12-and 18-month survival rates of 74.3, 41.3, and 24.3%. Patients with a prognostic class of 3 had a median survival of 6.8 months, with a 6-, 12-, and 18-month survival rate of 57.6, 25.8, and 13.1%. Patients with a prognostic class of 4 had a median survival of 6.1 months, with a 6-, 12-, and 18-month survival rate of 50.0, 14.32, and 3.6%. * These factors were independent of perioperative variables previously shown to be associated with survival (GTR, carmustine wafer implantation, temozolomide chemotherapy, and radiation therapy). In a separate multivariate model, age and KPS score were dichotomized and included into the multivariate analysis with motor deficit, language deficit, and periventricular tumor location. Age > 60 years and KPS ≤ 80 years had the greatest statistical association among age and KPS values. † Perioperative factors that were controlled for in the multivariate model.
In Log-rank analysis, the survival for patients with different prognostic classes was statistically significant (p < 0.05) (Fig. 1) . Patients with a prognostic class of 1 had a statistically longer survival than patients with a class of 2 (p < 0.0001), 3 (p < 0.0001), or 4 (p < 0.0001). Likewise, patients with a prognostic class of 2 had a statistically longer survival than patients with a class of 3 (p = 0.002) or 4 (p < 0.0001). Finally patients with a prognostic class of 3 had a statistically longer survival than patients with a class of 4 (p = 0.04). Furthermore, in subgroup analysis, after only comparing patients in whom GTR was achieved, the different prognostic classes remained statistically different (p < 0.05). The different prognostic classes also remained statistically different after comparing only patients who received both temozolomide and radiation therapy (p < 0.05).
Furthermore, to make sure that age and KPS were not dominating the survival curves, separate Kaplan-Meier and Log-rank analyses were performed. Patients were assigned one point each if they presented with a preoperative motor deficit, preoperative language deficit, and/or a periventricular tumor. Patients with 0, 1, and 2-3 points had a median survival of 14.5, 10.2, and 8.0 months, respectively. Patients with 0 points had significantly longer survival times than patients with 1 (p = 0.003) and 2-3 points (p < 0.0001). Likewise, patients with 1 point had significantly longer survival times than patients with 2-3 points (p = 0.001). These findings validate the use of motor deficit, language deficit, and periventricular tumor location in this prognostic classification scheme.
Discussion
In this series of 393 patients with intracranial primary GBM, 310 (79%) patients had died as of the most recent follow-up. The median survival of the entire cohort was 11.9 months, where the 6-, 12-, and 18-month survival rates were 74.3, 45.1, and 28.9%, respectively. After controlling for perioperative factors consistently shown to be associated with survival (extent of resection, carmustine wafer therapy, temozolomide chemotherapy, and radiation therapy), the preoperative factors independently associated with shortened survival were older age, poor functional status, motor deficit, language deficit, and periventricular tumor location. Patients with more of these preoperative variables had statistically significantly poorer survival, regardless of perioperative treatment.
Preoperative Factors Independently Associated With Survival
Older age was associated with poorer survival in this study. The age category most significantly associated with poor survival was age > 60 years. Similar findings have been reported in prior studies. 18, 19 Older age may lead to a decreased ability for a patient to withstand neurological insults caused by the tumor, surgery, and/or adjuvant therapy. 16, 18, 19 Furthermore, older patients may harbor tu mors with different molecular profiles and resistance genes that confer a more aggressive behavior. 1, 27, 32 These features may be the reasons why older patients with GBM tend to have poorer outcomes.
Patients with poor preoperative functional status in this study tended to have decreased survival times. In fact, among KPS score categories, KPS score ≤ 80 had the most significant association with poor survival. As with age, this finding has been documented in previous studies of both low-and high-grade gliomas. 16, 18, 19 Patients with higher preoperative neurological function may be able to better tolerate neurological insults caused by the tumor, surgery, and/or adjuvant therapy. 16, 18, 19 This toleration may lead to better survival times.
Patients who presented with motor and/or language deficits, independent of preoperative KPS score, had significantly decreased survival rates in this study. Patients with motor deficits had a 40% decreased survival compared with patients without motor deficits, while patients with language deficits had a 60% decreased survival as compared with patients without language deficits. Interestingly, the location of the tumor including motor/sensory and language cortex on preoperative MR imaging was not significantly associated with survival. The presence of these deficits may therefore indicate a more infiltrative tumor, with extension beyond what can be identified on preoperative imaging. These tumors may often infiltrate subcortical pathways as well.
Patient with tumors immediately adjacent to the lateral ventricles had a 30% decreased survival rate compared with those whose tumors did not abut the lateral ventricles. This periventricular region has been an area of increased scrutiny in both basic science 25, 26, 28 and clinical studies. 4, 20, 23 This region, which has been called the subventricular zone, has been found to be a source of stemlike cells with self-renewal and multipotential capabilities. 25, 26, 28 There is also a growing belief that this site may 
* In this scoring system, patients with a prognostic class of 1 had 0-1 points, class 2 had 2 points, class 3 had 3 points, and class 4 had 4-5 points. be a source of tumors with higher self-renewal, proliferative, and/or invasive capacities leading to poorer patient outcomes. 25 
Preoperative Classification Scale
Previous classification schemes have been devised for patients with low-grade gliomas 5 and patients with malignant gliomas (anaplastic gliomas and GBM). 7 These studies, however, may be limited in their applicability for patients with GBM. Chang et al. 5 devised a preoperative classification system for adult patients with hemispheric low-grade gliomas (fibrillary astrocytomas, oligodendrogliomas, oligoastrocytomas). This system used age > 50 years, KPS ≤ 80, presumed eloquent brain location (sensorimotor, language, basal ganglia, thalamus, visual cortex), and tumor size > 4 cm to categorize patients preoperatively. Curran et al. 7 used recursive portioning analysis (RPA) to design a regression tree for patients with anaplastic gliomas and GBM treated at several different institutions between 1974 and 1989. This RPA used age < 50, histology (anaplastic glioma vs GBM), and presence of altered mental status to define study subgroups. These prior analyses are limited by their inclusion of patients with non-GBM pathologies, 5,7 lack of more contemporary adjuvant therapies, 7 and lack of control for factors known to be associated with survival. 5, 7 An effective preoperative classification scale for patients with intracranial GBM has yet to be devised. A classification system that predicts survival, however, would be useful because there is no standard for guiding surgical and medical management as there is for patients with arteriovenous malformations, 30 intracranial hemorrhage, 14 or spinal injury. 11 Additionally, survival for patients with GBM is extremely unpredictable, with heterogeneous survival times. 33 An effective classification system based on preoperative risk factors could allow clinicians to prognosticate survival as well as possibly help guide surgical and medical strategies.
Based on this premise, we devised a preoperative classification scale using factors independently associated with survival (Table 3 ). This classification system identifies 4 distinct populations with statistically different survival rates. Importantly, these classes are independent of perioperative factors known to be associated with survival, including extent of resection, 17, 19, 22 carmustine wafer implantation, 2,34 temozolomide chemotherapy, 12,31 and radiation therapy. 10 These prognostic classes can therefore be applied before any treatment is pursued. This would allow physicians and patients to prognosticate survival, which could play an important role in developing individualized surgical and medical approaches.
Strengths and Limitations
We believe this study provides several useful insights. First, studies ascertaining preoperative factors associated with survival are few and limited. The present study not only confirms the associations of older age and impaired functional status with decreased survival, but also adds motor and language deficits as well as periventricular tumor location. Second, studies applying preoperative risk factors in a manner that provides useful prognostic information have yet to be conducted. This study provides a potentially useful 4-class system that may prognosticate survival independent of perioperative factors before any treatment is pursued. Lastly, this study may provide useful information that may help guide treatment strategies aimed at prolonging survival for patients with GBM.
This study, however, has some limitations. One limitation is the need for external validation of this prognostic classification scale and its applicability in a prospectively followed cohort. Both of these processes are currently ongoing. This study also does not analyze the prognostic implication of molecular markers and genotypes that may also be linked to patient outcomes. In recent studies, patients with GBM and O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation had prolonged survival after temozolomide and radiation therapy as compared with patients without this molecular marker. 13 More recently, Parsons et al. 24 performed a genomic analysis in patients with GBM and found that patients with isocitrate dehydrogenase 1 (IDH1) mutations had prolonged survival times. These molecular markers and others may be associated with survival but were not analyzed in this study. Furthermore, the majority of patients in this study did not undergo GTR and/or receive triple combinatorial adjuvant therapy (carmustine wafer, temozolomide, radiation). As a result, the relevance of this prognostic model may be altered in the context of those patients receiving the most aggressive of treatment regimens. Additionally, this study is inherently limited by its retrospective design, and, as a result, it is not appropriate to infer direct causal relationships. However, we tried to create a uniform patient population by utilizing strict inclusion and exclusion criteria, thus providing more relevant information for patients with primary intracranial GBM. We included only adult patients with primary GBM since children and patients with secondary GBM may have tumors with different molecular and cytogenic profiles. 1, 27, 32 In addition, we excluded patients with incomplete medical records and patients who had undergone prior resections, had received previous adjuvant therapies, had undergone needle biopsies, and had infratentorial tumors. Furthermore, we performed multivariate analyses and controlled for potential perioperative confounding variables. Given these statistical controls and a relatively precise outcome measure, we believe our findings offer useful insights into the management of patients with primary GBM. However, prospective studies are needed to provide better data to guide clinical decision-making.
Conclusions
Individual survival for patients with intracranial GBM is heterogeneous, with some patients surviving for a few months and others for several years. The ability to predict which patients will have better outcomes is limited. The present study demonstrated that older age, poor performance status, motor deficit, language deficit, and periventricular tumor location independently predicted shortened survival regardless of extent of resection and adjuvant therapies. A classification system based on these factors was able to identify 4 distinct groups of patients with different survival rates. This classification system, based on preoperative variables, may provide patients and physicians with prognostic information that may be used to guide medical and surgical therapy. 
